These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 25270681)

  • 21. Global long-term study on motor and non-motor symptoms and safety of levodopa-carbidopa intestinal gel in routine care of advanced Parkinson's disease patients; 12-month interim outcomes.
    Antonini A; Yegin A; Preda C; Bergmann L; Poewe W;
    Parkinsonism Relat Disord; 2015 Mar; 21(3):231-5. PubMed ID: 25585993
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Levodopa-carbidopa intestinal gel (LCIG) treatment in routine care of patients with advanced Parkinson's disease: An open-label prospective observational study of effectiveness, tolerability and healthcare costs.
    Pålhagen SE; Sydow O; Johansson A; Nyholm D; Holmberg B; Widner H; Dizdar N; Linder J; Hauge T; Jansson R; Bergmann L; Kjellander S; Marshall TS
    Parkinsonism Relat Disord; 2016 Aug; 29():17-23. PubMed ID: 27318707
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical and economic results of bilateral subthalamic nucleus stimulation in Parkinson's disease.
    Fraix V; Houeto JL; Lagrange C; Le Pen C; Krystkowiak P; Guehl D; Ardouin C; Welter ML; Maurel F; Defebvre L; Rougier A; Benabid AL; Mesnage V; Ligier M; Blond S; Burbaud P; Bioulac B; Destée A; Cornu P; Pollak P;
    J Neurol Neurosurg Psychiatry; 2006 Apr; 77(4):443-9. PubMed ID: 16543519
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interim analysis of long-term intraduodenal levodopa infusion in advanced Parkinson disease.
    Pålhagen SE; Dizdar N; Hauge T; Holmberg B; Jansson R; Linder J; Nyholm D; Sydow O; Wainwright M; Widner H; Johansson A
    Acta Neurol Scand; 2012 Dec; 126(6):e29-33. PubMed ID: 22690905
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cabergoline versus levodopa monotherapy: a decision analysis.
    Smala AM; Spottke EA; Machat O; Siebert U; Meyer D; Köhne-Volland R; Reuther M; DuChane J; Oertel WH; Berger KB; Dodel RC
    Mov Disord; 2003 Aug; 18(8):898-905. PubMed ID: 12889079
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Direct switch from conventional levodopa to stalevo (levodopa/carbidopa/entacapone) improves quality of life in Parkinson's disease: results of an open-label clinical study].
    Litvinenko IV; Odinak MM; Mogil'naia VI; Sologub OS; Sakharovskaia AA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2009; 109(1):51-4. PubMed ID: 19156087
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness of subthalmic nucleus deep brain stimulation for the treatment of advanced Parkinson disease in Hong Kong: a prospective study.
    Zhu XL; Chan DT; Lau CK; Poon WS; Mok VC; Chan AY; Wong LK; Yeung JH; Leung MC; Tang VY; Wong RK; Yeung C
    World Neurosurg; 2014 Dec; 82(6):987-93. PubMed ID: 25175275
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness of continuous subcutaneous apomorphine in the treatment of Parkinson's disease in the UK and Germany.
    Walter E; Odin P
    J Med Econ; 2015 Feb; 18(2):155-65. PubMed ID: 25348011
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Duopa--a carbidopa/levodopa enteral suspension for Parkinson's disease.
    Med Lett Drugs Ther; 2015 Aug; 57(1474):112. PubMed ID: 26218794
    [No Abstract]   [Full Text] [Related]  

  • 30. Levodopa-Carbidopa Intestinal Gel Infusion Therapy in Advanced Parkinson's Disease: Single Middle Eastern Center Experience.
    Bohlega S; Abou Al-Shaar H; Alkhairallah T; Al-Ajlan F; Hasan N; Alkahtani K
    Eur Neurol; 2015; 74(5-6):227-36. PubMed ID: 26618531
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost analysis of ropinirole versus levodopa in the treatment of Parkinson's disease.
    Iskedjian M; Einarson TR
    Pharmacoeconomics; 2003; 21(2):115-27. PubMed ID: 12515573
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reducing uncertainty in value-based pricing using evidence development agreements: the case of continuous intraduodenal infusion of levodopa/carbidopa (Duodopa®) in Sweden.
    Willis M; Persson U; Zoellner Y; Gradl B
    Appl Health Econ Health Policy; 2010; 8(6):377-86. PubMed ID: 21043539
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of healthcare utilization and health status of patients with Parkinson's disease treated with deep brain stimulation of the subthalamic nucleus.
    Spottke EA; Volkmann J; Lorenz D; Krack P; Smala AM; Sturm V; Gerstner A; Berger K; Hellwig D; Deuschl G; Freund HJ; Oertel WH; Dodel RC
    J Neurol; 2002 Jun; 249(6):759-66. PubMed ID: 12111311
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacoeconomic analysis of using Sinemet CR over standard Sinemet in parkinsonian patients with motor fluctuations.
    Hempel AG; Wagner ML; Maaty MA; Sage JI
    Ann Pharmacother; 1998 Sep; 32(9):878-83. PubMed ID: 9762373
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost effectiveness of rasagiline and pramipexole as treatment strategies in early Parkinson's disease in the UK setting: an economic Markov model evaluation.
    Haycox A; Armand C; Murteira S; Cochran J; François C
    Drugs Aging; 2009; 26(9):791-801. PubMed ID: 19728752
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost analysis of the treatments for patients with advanced Parkinson's disease: SCOPE study.
    Valldeoriola F; Puig-Junoy J; Puig-Peiró R;
    J Med Econ; 2013; 16(2):191-201. PubMed ID: 23035627
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Costs of drug treatment in Parkinson's disease.
    Dodel RC; Eggert KM; Singer MS; Eichhorn TE; Pogarell O; Oertel WH
    Mov Disord; 1998 Mar; 13(2):249-54. PubMed ID: 9539337
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intrajejunal levodopa infusion in advanced Parkinson's disease: long-term effects on motor and non-motor symptoms and impact on patient's and caregiver's quality of life.
    Fasano A; Ricciardi L; Lena F; Bentivoglio AR; Modugno N
    Eur Rev Med Pharmacol Sci; 2012 Jan; 16(1):79-89. PubMed ID: 22338551
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of dyskinesias in Parkinson's disease on quality of life and health-related costs: a prospective European study.
    Péchevis M; Clarke CE; Vieregge P; Khoshnood B; Deschaseaux-Voinet C; Berdeaux G; Ziegler M;
    Eur J Neurol; 2005 Dec; 12(12):956-63. PubMed ID: 16324089
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term intraduodenal infusion of a water based levodopa-carbidopa dispersion in very advanced Parkinson's disease.
    Nilsson D; Hansson LE; Johansson K; Nyström C; Paalzow L; Aquilonius SM
    Acta Neurol Scand; 1998 Mar; 97(3):175-83. PubMed ID: 9531434
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.